Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002
Retrieved on:
Thursday, November 12, 2020
The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound, NVK-002, to slow the progression of myopia in children.
Key Points:
- The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound, NVK-002, to slow the progression of myopia in children.
- It is currently under clinical evaluation in the CHAMP study and has entered Phase 3 clinical trial in the US and Europe.
- CHAMP is a 576 subject, randomized, placebo-controlled, double-masked study evaluating the effects of NVK-002 on myopia progression in children.
- Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. is a wholly owned subsidiary of Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology"), which specializes in the development, manufacturing and marketing of ophthalmic drugs.